Literature DB >> 24637698

Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures.

Loretta Franceschi1, Piergiorgio Cojutti, Massimo Baraldo, Federico Pea.   

Abstract

Administration by continuous infusion may represent an effective tool for the treatment of multidrug-resistant gram-negative related infections with meropenem. Currently, no data on chemical stability of generic bioequivalent versions of meropenem over time are available. Triplicate samples of 5 mg/mL solutions of a generic meropenem formulation, Hospira, were evaluated for chemical stability at increasing temperatures (25°C, 30°C, 35°C, and 40°C) by means of a high-performance liquid chromatography technique over 4 separate days. Degradation of generic meropenem was both time and temperature dependent, and the aqueous solutions were stable for up to 8 hours in the temperature range between 25°C and 35°C, and for up to 5 hours at 40°C. Continuous infusion of generic meropenem Hospira may be applied in clinical settings with ambient temperature below 35°C, provided that the 5 mg/mL aqueous solution is reconstituted at most after 6-8 hours.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24637698     DOI: 10.1097/FTD.0000000000000054

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  11 in total

1.  Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients.

Authors:  Piergiorgio Cojutti; Natalia Maximova; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

2.  Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.

Authors:  Manjunath P Pai; Piergiorgio Cojutti; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2015-09       Impact factor: 6.447

3.  Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.

Authors:  Hui-Ying Zhao; Jian Gu; Jie Lyu; Dan Liu; Yi-Tong Wang; Fang Liu; Feng-Xue Zhu; You-Zhong An
Journal:  Chin Med J (Engl)       Date:  2017-05-20       Impact factor: 2.628

Review 4.  Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis.

Authors:  Zhenwei Yu; Xiaoping Pang; Xuqi Wu; Chunlei Shan; Saiping Jiang
Journal:  PLoS One       Date:  2018-07-30       Impact factor: 3.240

Review 5.  Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years.

Authors:  Ling-Ling Zhu; Quan Zhou
Journal:  Infect Drug Resist       Date:  2018-08-08       Impact factor: 4.003

6.  An investigation of the stability of meropenem in elastomeric infusion devices.

Authors:  Finbarr Foy; Giuseppe Luna; Jorge Martinez; Zach Nizich; Jason Seet; Katie Lie; Bruce Sunderland; Petra Czarniak
Journal:  Drug Des Devel Ther       Date:  2019-08-01       Impact factor: 4.162

7.  Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study.

Authors:  Pier Giorgio Cojutti; Davide Lazzarotto; Anna Candoni; Maria Vittoria Dubbini; Maria Elena Zannier; Renato Fanin; Federico Pea
Journal:  J Antimicrob Chemother       Date:  2020-10-01       Impact factor: 5.790

8.  Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.

Authors:  Laurens Manning; Cameron Wright; Paul R Ingram; Timothy J Whitmore; Christopher H Heath; Ingrid Manson; Madhu Page-Sharp; Sam Salman; John Dyer; Timothy M E Davis
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

9.  Investigation of meropenem stability after reconstitution: the influence of buffering and challenges to meet the NHS Yellow Cover Document compliance for continuous infusions in an outpatient setting.

Authors:  Conor Jamieson; Michael Charles Allwood; Donata Stonkute; Andrew Wallace; Alan-Shaun Wilkinson; Tim Hills
Journal:  Eur J Hosp Pharm       Date:  2019-01-13

10.  Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization.

Authors:  Pier Giorgio Cojutti; Milo Gatti; Matteo Rinaldi; Tommaso Tonetti; Cristiana Laici; Chiara Mega; Antonio Siniscalchi; Maddalena Giannella; Pierluigi Viale; Federico Pea
Journal:  Front Pharmacol       Date:  2021-12-08       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.